Lecanemab Favors Early Aggregates. Fluorescently labeled lecanemab (green) bound most strongly to soluble Aβ aggregates ...

In late 2022, the results of a groundbreaking stage-three trial for a ‘miracle’ new Alzheimer’s drug, lecanemab, were hailed ...

Donanemab: What is the new Alzheimer’s drug rejected by the NHS? - Donanemab and another new drug for Alzheimer’s called ...

HealthDay News — Annual wasteful spending on discarded lecanemab is anticipated to range between $133 and $336 million, given current vial sizes, according to a research letter published online ...

Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval ...

Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...

A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England ...

Medicare could save up to 74% of the money lost from discarded Alzheimer's drug lecanemab by the simple introduction of a new vial size that would reduce the amount of unused medication that is thrown ...

The Therapeutic Goods Administration (TGA) has made the decision not to register lecanemab (LEQEMBI) for the treatment of patients with Mild Cognitive ...

STOCKHOLM, Oct. 16, 2024 /PRNewswire/ --BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia issued a public ...

Eisai will request a reconsideration of this initial decision under Section 60 of the Therapeutic Goods Act within 90 days to make lecanemab available for eligible people living with early AD in ...

Eisai will request a reconsideration of this initial decision under Section 60 of the Therapeutic Goods Act within 90 days to make lecanemab available for eligible people living with early AD in ...